Categories: CancerNews

RaySearch Laboratories: Interim report July – September 2024

STOCKHOLM, Nov. 8, 2024 /PRNewswire/ — 

THIRD QUARTER (JULY – SEPTEMBER 2024)

  • Order intake SEK 253.4 M (240.7)
  • Net sales SEK 293.3 (252.9)
  • Operating profit SEK 61.8 M (28,6)
  • Profit after tax SEK 45.4 M (21,6)
  • Earnings per share before/after dilution SEK 1.32 (0.63)
  • Cash flow from operating activities SEK 60.5 M (124.4)
  • Order backlog SEK 1,732.0 M (1,966.3) at the end of the period

NINE MONTHS (JANUARY – SEPTEMBER 2024)

  • Order intake SEK 782.1 M (686.5)
  • Net sales SEK 869.4 M (722.5)
  • Operating profit SEK 186.9 M (70.5)
  • Profit after tax SEK 143.5 M (50.0)
  • Earnings per share before/after dilution SEK 4.19 (1.46)
  • Cash flow from operating activities SEK 382.3 M (340.2)

SIGNIFICANT EVENTS DURING THE SECOND QUARTER

  • Connect Proton Therapy Center in the USA has placed an order for RayStation
  • Iridium Network first center in the world to use RayCare with TrueBeam to treat a patient

SIGNIFICANT EVENTS AFTER THE END OF THE REPORTING PERIOD

  • GenesisCare in the UK has placed an order for RayStation
  • RaySearch now has more than 100 RayStation customers in China
  • Three centers in the French Unicancer network choose RayStation
  • Nina Grönberg has been appointed as the new CFO and will take office in January 2025
  • Institut Curie selects RayStation for proton planning
  • The Board has decided to raise the target for the operating margin to at least 25 (20) percent by 2026

WEBCAST

CEO Johan Löf and Interim CFO Annika Blondeau Henriksson will present RaySearch’s interim report for July-September 2024 in a webcast to be held in English on Friday, November 8, 2024, at 10:00 a.m. CET.

Link to webcast: RaySearch Q3, 2024

The information contained in this interim report is such that RaySearch Laboratories AB (publ) is obliged to disclose under the EU Market Abuse Regulation and the Swedish Securities Market Act. The information was submitted for publication on November 8, 2024, at 7:45 a.m. CET.

FOR MORE INFORMATION, PLEASE CONTACT:
Johan Löf, founder and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
johan.lof@raysearchlabs.com

Annika Blondeau Henriksson, Interim CFO, RaySearch Laboratories AB (publ)
Telephone: +46 (0) 8 510 530 00
annika.henriksson@raysearchlabs.com

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/raysearch-laboratories/r/interim-report-july—september-2024,c4063330

The following files are available for download:

 

View original content:https://www.prnewswire.com/news-releases/raysearch-laboratories-interim-report-july–september-2024-302299745.html

SOURCE RaySearch Laboratories

Staff

Recent Posts

Aulisa® Medical Expands Access with New Leasing Options for Procuring Advanced Monitoring Solutions

PALO ALTO, Calif., Nov. 7, 2024 /PRNewswire/ -- Aulisa® Medical USA, Inc., a leader in…

9 hours ago

Shanghai thriving as global investment hub

BEIJING, Nov. 7, 2024 /PRNewswire/ -- A news report from chinadaily.com.cn: The 2024 Shanghai City Investment…

9 hours ago

Medexus Announces Strong Fiscal Q2 2025 Results

Fiscal Q2 2025 revenue of $26.3 million, net income of $0.1 million, operating income of…

15 hours ago

Front Porch announces Brain and Balance Center in Carlsbad, California

Carlsbad By The Sea senior living community develops innovative, empowering program CARLSBAD, Calif., Nov. 7,…

15 hours ago

NUTEX HEALTH REPORTS THIRD QUARTER AND YEAR TO DATE SEPTEMBER 30, 2024 FINANCIAL RESULTS

TOTAL REVENUE OF $222.3 MILLION FOR THE FIRST NINE MONTHS OF 2024 VS. $178.0 MILLION…

15 hours ago

Solventum Reports Third Quarter 2024 Financial Results and Raises Full-Year Guidance

Reported sales increased 0.4% to $2.082 billion; organic sales increased 0.3%GAAP Earnings Per Share (EPS)…

15 hours ago